Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1059-1067

  Wild, Damian ^a,b   Wicki, Andreas ^c   Mansi, Rosalba ^a,d   Béhé, Martin ^d,e   Keil, Boris ^e   Bernhardt, Peter ^f   Christofori, Gerhard ^c   Ell, Peter J ^b   Mäcke, Helmut R ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

68Ga; 99mTc; Exendin 4; Glucagon like peptide 1 receptor; Insulinoma

Indexed keywords

[LYSINE 40 (6 AMINOHEXANOIC ACID 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID)]EXENDIN 4 GA 68; [LYSINE 40 (6 AMINOHEXANOIC ACID 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID)]EXENDIN 4 IN 111; [LYSINE 40 (6 AMINOHEXANOIC ACID HYDRAZINONICOTINAMIDE ETHYLENEDIAMINEDIACETIC ACID)]EXENDIN 4 TC 99M; [LYSINE 40 (6 AMINOHEXANOIC ACID HYDRAZINONICOTINAMIDE)]EXENDIN 4 TC 99M; EXENDIN 4; GELATIN SUCCINATE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; POLYGLUTAMIC ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GALLIUM; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; INDIUM; PEPTIDE; TECHNETIUM DERIVATIVE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; IMAGE QUALITY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL CARCINOGENESIS; PANCREAS ISLET CELL CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSGENIC MOUSE; ANIMAL; CELL CULTURE; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; KIDNEY; METABOLISM; RADIATION RESPONSE; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GALLIUM RADIOISOTOPES; INDICATORS AND REAGENTS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; KIDNEY; MALE; MICE; MICE, TRANSGENIC; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, GLUCAGON; TECHNETIUM COMPOUNDS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENOMS;

EID: 77954986457     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.074914     Document Type: Article

References (41)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
2. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods. 2009;48:161-177.
3. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol. 2001;37:8-17.
4. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
5. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853-858.
6. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology. 1997;112:583-590.
7. Zimmer T, Stolzel U, Bader M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut. 1996;39:562-568.
8. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
9. Chatziioannou A, Kehagias D, Mourikis D, et al. Imaging and localization of pancreatic insulinomas. Clin Imaging. 2001;25:275-283.
10. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl 4):iv1-iv16.
11. 18F-DOPA) positron emission tomography as a tool to localize an insulinoma or β-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237-1244.
12. 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab. 2010;95:303-307.
13. Wiesli P, Brandle M, Schmid C, et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol. 2004;15:1251-1256.
14. Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264-275.
15. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagonlike peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging. 2002;29:597-606.
16. Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept. 2006;137:162-167.
17. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025-2033.
18. 2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res. 2007;13:3696-3705.
19. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
20. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-4405.
21. IUPAC-IUB Commission on Biochemical Nomenclature (CBN). Symbols for amino-acid derivatives and peptides, recommendations 1971. Eur J Biochem. 1972;27:201-207.
22. Schramm NU, Ebel G, Engeland U, Schurrat T, Behe M, Behr TM. Highresolution SPECT using multi-pinhole collimation. IEEE Trans Nucl Sci. 2003;50:315-320.
23. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
24. 68Ga for medical application. J Nucl Med. 2007;48:1741-1748.
25. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 1985;315:115-122.
26. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
27. International Commission on Radiological Protection (ICRP). Recommendations of the International Commission on Radiological Protection. ICRP publication 60. Oxford, U. K.: Pergamon Press; 1991.
28. Gotthardt M, van Eerd-Vismale J, Oyen WJ, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med. 2007;48:596-601.
29. Martin WH, Delbeke D, Patton JA, Sandler MP. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose. Radiology. 1996;198:225-231.
30. Gouya H, Vignaux O, Augui J, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR. 2003;181:987-992.
31. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-993.
32. 3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
33. 18F-FDG. Cancer. 2008;112:2447-2455.
34. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-1438.
35. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
36. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1):172S-178S.
37. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876-913.
38. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-743.
39. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem. 2008;56:841-851.
40. Brom M, Baumeister P, Melis M, et al. Determination of the β-cell mass by SPECT imaging with In-111-DTPA-exendin-3 in rats [abstract]. J Nucl Med. 2009;50(suppl 2):147.
41. 68Ga- labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. January 29, 2010 [Epub ahead of print].